Preliminary results presented in 2022 and 2023 indicate that thrombocytopenia due BCL-XL inhibition in platelets was not observed upon treatment with ABBV-155, suggesting that an antibody-targeted approach may indeed circumvent unwanted side effects of BCL-XL inhibition.441,442 However, in this heavily pre-treated patient cohort, ABBV-155 also did not show anti-tumor activity, and this molecule has now been discontinued by Abbvie. The gene discussed is BCL2L1; the disease is neoplasm.